ClinicalTrials.gg
CompletedNCT06828055Updated Oct 6, 2025

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

A Phase 2 interventional study of Placebo and VK2735 in Weight Loss, sponsored by Viking Therapeutics, Inc.. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Viking Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 998 studies in Weight Loss with a site in United States — 117 open to participants now, 172 under way, 8 of them phase 3. Weight Loss · United States.

Enrollment
141st of 915
280 · median 72
Started
2024
with 42 others
Phase 2
85 of 998
12 open now
Registered
904th of 998
by date

Among the 998 studies in Weight Loss with a site in United States, this one is the 141st largest by enrollment of the 915 interventional ones that give a count, is one of 43 that started in 2024, is one of 85 in phase 2, and was the 904th registered.

Weight Loss

1,818 studies on the registry are indexed under Weight Loss; 296 are open to participants now.

Browse Weight Loss studies →

Open to participants now

117 of the 998 studies in Weight Loss with a site in United States are open now. Recruiting first, the newest first:

112 more — sign in →

All 117 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Weight Loss studies recruiting now, 71 (36%) set no upper age limit and 108 (55%) stop at 75 or younger; 21 take children under 18; 58 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 998 studies in Weight Loss with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.

VK2735 or matched placebo will be administered once daily.

03

Conditions studied

  • Weight Loss

Browse trials for

Keywords

  • Overweight Obese
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years of age at the time of signing the .
  2. (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2

    • Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
    • BMI calculated at the Screening visit will be used to determine eligibility.

Exclusion criteria

Exclusion Criteria:

  1. History of or current medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation
  2. Self-reported body weight change of 5% or more within 3 months of screening
  3. Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)
  4. Current or past diagnosis of chronic pancreatitis
  5. Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)
  6. Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening
  7. Any prescription or over-the-counter medications intended for weight loss within 6 months of screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
280 participants (actual)

Study arms

  • Placebo comparator
    Placebo Assignment

    VK2735 (Placebo) administered Daily

    Drug: Placebo

  • Experimental
    Active Assignment (Dose #1)

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily

    Drug: VK2735

  • Experimental
    Active Assignment (Dose #2)

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily

    Drug: VK2735

  • Experimental
    Active Assignment (Dose #3)

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily

    Drug: VK2735

  • Experimental
    Active Assignment (Dose #4)

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily

    Drug: VK2735

  • Experimental
    Active Assignment (Dose #5)

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily

    Drug: VK2735

  • Experimental
    Active Assignment (Dose #6)

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily

    Drug: VK2735

Interventions

  • DrugPlacebo

    Matching Placebo to VK2735

  • DrugVK2735

    Active Treatment

06

What researchers measure

Primary outcomes

  1. Percent (relative) change from baseline in body weight after 13 weeks of treatment

    To measure the efficacy of oral VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

    Time frame: 13 Weeks

Secondary outcomes

  1. Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13. Observed and change from baseline in body weight (kg) after 13 weeks of treatment

    To measure the efficacy of oral VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

    Time frame: 13 Weeks

Other outcomes

  1. Incidence of Treatment-emergent Adverse Events, incidence of Treatment-Emergent Serious Adverse Events and incidence of Adverse Events of Special Interest

    To evaluate the safety and tolerability of oral VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

    Time frame: 13 Weeks

07

Study locations

15 sites
  • Viking Clinical Site #111
    Peoria, Arizona 85381, United States
  • Viking Clinical Site #105
    Lake Forest, California 96230, United States
  • Viking Clinical Site #101
    Clearwater, Florida 33756, United States
  • Viking Clinical Site #108
    Largo, Florida 33777, United States
  • Viking Clinical Site #107
    Ocoee, Florida 34761, United States
  • Viking Clinical Site #102
    Port Orange, Florida 32127, United States
  • Viking Clinical Site #100
    Indianapolis, Indiana 46260, United States
  • Viking Clinical Site #110
    Louisville, Kentucky 40213, United States
  • Viking Clinical Site #114
    Marrero, Louisiana 70072, United States
  • Viking Clinical Site #109
    City of Saint Peters, Missouri 63303, United States
  • Viking Clinical Site #112
    Kansas City, Missouri 64131, United States
  • Viking Clinical Site #113
    Butte, Montana 59701, United States
  • Viking Clinical Site #103
    Knoxville, Tennessee 37909, United States
  • Viking Clinical Site #104
    Austin, Texas 78705, United States
  • Viking Clinical Site #106
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jun 2025, 6 months.

Of 44 phase 2 interventional studies under Weight Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 14, 2025
StartActual
Dec 18, 2024
Primary completionActual
Jun 24, 2025
CompletionActual
Aug 15, 2025
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06828055
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Dec 18, 2024
Primary completion
Jun 24, 2025
Completion
Aug 15, 2025
Last update
Oct 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VK2735

Start the discussion